Autoimmune & Inflammation — Peptide Research Overview
Chronic inflammation underlies most major chronic diseases, from autoimmune conditions to cardiovascular disease and neurodegenerative disorders. Several peptide compounds target core inflammatory signaling pathways — NF-κB, cytokine production, and immune cell trafficking — with potential applications across a broad range of inflammatory conditions.
Relevant Compounds
- BPC-157 — Reduces systemic and local inflammation via NO pathway modulation and downregulation of inflammatory cytokines. Evidence in gut, joint, and vascular inflammation models.
- KPV — Potent NF-κB inhibitor. Studied specifically in gut inflammation, but mechanism applies broadly to inflammatory conditions.
- Thymosin Alpha-1 — Immune modulator that reduces excessive inflammatory signaling while supporting appropriate immune responses. Used in sepsis, hepatitis, and autoimmune conditions internationally.
What the Research Shows
BPC-157
[Animal Study] BPC-157 demonstrates consistent anti-inflammatory effects across multiple organ systems in rodent models. Proposed mechanisms include: suppression of TNF-alpha and IL-6 production, modulation of the NO/NOS pathway to reduce oxidative inflammatory signaling, and promotion of angiogenesis to restore blood flow in ischemic inflammatory lesions. Its broad activity profile across different tissue types is unusual among peptide compounds.
KPV
[Animal Study / Preliminary] As a fragment of alpha-MSH (a natural anti-inflammatory hormone), KPV inherits potent anti-inflammatory activity with excellent safety profile. It directly enters intestinal epithelial cells and immune cells, where it blocks IκB kinase activation and prevents NF-κB nuclear translocation — effectively interrupting the central inflammation amplification pathway. Murine IBD models show significant reduction in histological inflammation scores.
Thymosin Alpha-1
[Human Trial] In addition to its immune-stimulating role, Thymosin Alpha-1 acts as a biological response modifier — enhancing immunity when it is insufficient and dampening excessive inflammatory responses in hyperactivated immune states. Human trials in sepsis show reduced mortality and shorter ICU stays, likely through restoration of T-regulatory cell function and normalization of cytokine storm dynamics.
Evidence Summary
| Compound | Evidence Level | Primary Mechanism |
|---|---|---|
| BPC-157 | Animal / Preliminary Human | NO modulation, cytokine suppression, angiogenesis |
| KPV | Animal / Preliminary | NF-κB inhibition, IκB kinase blockade |
| Thymosin Alpha-1 | Human Trial | T-reg restoration, cytokine normalization |
Research Disclaimer
No compound listed on this page is FDA-approved for autoimmune conditions or general inflammation management. This page is an educational summary of existing research. Autoimmune conditions require specialist medical management. Consult your healthcare provider before using any peptide or experimental compound.
Track your compounds with Dosi
Log doses, monitor symptoms, and build a personal health timeline. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting any compound.